Publications

For a complete list of publications see:
ResearchGate
ResearcherID

Konda SK, Kelso C, Medan J, Sleebs BE, Phillips DR, Cutts SM and Collins JG (2016) Isolation and structural analysis of the covalent adduct formed between a bis-amino mitoxantrone analogue and DNA: a pathway to major-minor groove cross-linked adducts, Org Biomol Chem., 14(43): 10217-21.

Konda SK, Kelso C, Pumuye PP, Medan J, Sleebs BE, Cutts SM, Phillips DR, Collins JG (2016) Reversible and formaldehyde-mediated covalent binding of a bis-amino mitoxantrone analogue to DNA, Org Biomol Chem., 14(20): 4728-38.

Evison BJ, Sleebs BE, Watson KG, Phillips DR and Cutts SM (2016) Mitoxantrone, more than just another Topoisomerase II poison, Med Res Rev., 36: 248-99.

Cutts SM, Rephaeli A, Nudelman A, Ugarenko M and Phillips DR (2015) Potential therapeutic advantages of doxorubicin when activated by formaldehyde to function as a DNA adduct-forming agent, Curr Top Med Chem., 15: 1409-22.

Shekhar TM, Green MM, Rayner DM, Miles MA, Cutts SM and Hawkins CJ (2015) Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells, Mut Res., 777: 23-32.

Konda SK, Wang H, Cutts SM, Phillips DR and Collins JG (2015) Binding of pixantrone to DNA at CpA dinucleotide sequences and bulge structures, Org Biomol Chem., 13(21): 5972-82.

Tarasenko N, Cutts SM, Phillips DR, Berkovitch-Luria G, Bardugo-Nissim E, Weitman M, Nudelman A and Rephaeli A (2014) A novel valproic acid prodrug as an anticancer agent that enhances doxorubicin anticancer activity and protects normal cells against its toxicity in vitro and in vivo, Biochem Pharmacol., 88(2): 158-68.

Ankers EA, Evison BJ, Phillips DR, Brownlee RTC and Cutts SM (2014) Design, synthesis, and DNA sequence selectivity of formaldehyde-mediated DNA-adducts of the novel N-(4-aminobutyl) acridine-4-carboxamide, Bioorg Med Chem Lett., 24(24): 5710-15.

Rayner DM and Cutts SM (2014) Anthracyclines, The Side Effects of Drug Annual, 36: 683-94.

Forrest RA, Swift LP, Evison BJ, Rephaeli A, Nudelman A, Phillips DR and Cutts SM (2013) The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts, Cancer Chemother Pharmacol., 71(3): 809-16.

Forrest RA, Swift LP, Rephaeli A, Nudelman A, Kimura K-I, Phillips DR and Cutts SM (2012) Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation, Biochem Pharmacol., 83(12): 1602-12.

Bilardi RA, Kimura K-I, Phillips DR and Cutts SM (2012) Processing of anthracycline-DNA adducts via DNA replication and interstrand crosslink repair pathways, Biochem Pharmacol., 83(9): 1241-50.

Tarasenko N, Cutts SM, Phillips DR, Inbal A, Kessler-Icekson G-I, Nudelman A and Rephaeli A (2012) Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor, PLoS One, 7(2): e31393.

Tarasenko N, Kessler-Icekson G, Boer P, Inbal A, Schlesinger H, Phillips DR, Cutts SM, Nudelman A and Rephaeli A (2012) The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity, Invest New Drugs, 30(1): 130-43.

Evison BJ, Pastuovic M,  Bilardi RA, Forrest RA, Pumuye PP, Sleebs BE, Watson KG, Phillips DR and Cutts SM (2011) M2, a novel anthracenedione, elicits a potent DNA damage response that can be subverted through checkpoint kinase inhibition to generate mitotic catastrophe, Biochem Pharmacol., 82(11): 1604-18.